<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005944</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067833</org_study_id>
    <secondary_id>FRE-FNCLCC-97018</secondary_id>
    <secondary_id>EU-20010</secondary_id>
    <nct_id>NCT00005944</nct_id>
  </id_info>
  <brief_title>Second-look Surgery With or Without Intraperitoneal Chemotherapy in Treating Patients With Recurrent Colorectal Cancer</brief_title>
  <official_title>Study of Second Look Surgery With or Without Chemotherapy Intraperitoneally, in the Event of Risk of Intraperitoneal Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Giving chemotherapy drugs in different ways may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of second-look surgery with&#xD;
      or without intraperitoneal infusions of mitomycin and fluorouracil in treating patients who&#xD;
      have colorectal cancer that is recurrent to the peritoneum.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the effect of second look surgery with or without intraperitoneal&#xD;
      mitomycin and fluorouracil on the 3 year survival rate of patients with colorectal cancer who&#xD;
      are at high risk for peritoneal cavity cancer. II. Compare the quality of life of patients&#xD;
      treated with these regimens. III. Compare the toxicity of these regimens in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center, risk group, presence of symptoms (yes vs no), and isolated disease (yes vs no). After&#xD;
      primary surgery, all patients receive 6 months of chemotherapy consisting of leucovorin&#xD;
      calcium IV followed by fluorouracil IV over 10 minutes on days 1-5 every 4 weeks. Patients&#xD;
      then undergo second look surgery or laparoscopy at 8-12 months. Second look surgery or&#xD;
      laparoscopy may be performed earlier if markers increase progressively for unknown reasons or&#xD;
      symptoms of peritoneal cancer occur. Patients with recurrent disease that can be resected are&#xD;
      randomized to one of two treatment arms. Patients with no residual disease or with&#xD;
      unresectable disease are followed for survival. Arm I: Patients undergo complete resection of&#xD;
      all detectable lesions followed immediately by intraperitoneal (IP) mitomycin on day 0 and&#xD;
      fluorouracil IP on days 1-4. Patients also receive systemic chemotherapy consisting of&#xD;
      leucovorin calcium IV over 2 hours and fluorouracil IV bolus, followed by fluorouracil IV&#xD;
      over 22 hours on days 1 and 2. Systemic chemotherapy repeats every 2 weeks for 6 months. Arm&#xD;
      II: Patients undergo complete or partial resection and then receive systemic chemotherapy as&#xD;
      in arm I. Quality of life is assessed at baseline and then every 4 months for 3 years. All&#xD;
      patients (including nonrandomized patients) are followed every 4 months for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 152 patients (76 randomized) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insuffisient recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">July 1, 1999</start_date>
  <completion_date type="Actual">October 1, 2003</completion_date>
  <primary_completion_date type="Actual">October 24, 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Colorectal Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin C</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>laparoscopic surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Primary diagnosis of adenocarcinoma of the colon or rectum and&#xD;
        meeting one of the following risk criteria during the primary surgery: Perforated bowel&#xD;
        (spontaneous or not) Occlusion Peritoneal deposits Invasion of serosa of more than 4 cm&#xD;
        diameter Concurrent ovarian metastases Randomization eligibility: Presence of proven&#xD;
        recurrent peritoneal disease (only one micronodule of 1 mm sufficient) at second look&#xD;
        laparotomy Total resection of macroscopic lesions possible (local recurrence, lymph node or&#xD;
        hepatic metastases)&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 70 and under Performance status: Not specified Life&#xD;
        expectancy: Not specified Hematopoietic: WBC at least 1,500/mm3 Platelet count at least&#xD;
        100,000/mm3 Hepatic: Not specified Renal: Creatinine no greater than 1.4 mg/dL&#xD;
        Cardiovascular: No cardiac condition that would increase surgical risk Pulmonary: No&#xD;
        pulmonary condition that would increase surgical risk Other: No other condition that would&#xD;
        increase surgical risk No other malignancy within the past 5 years except basal cell skin&#xD;
        cancer&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No&#xD;
        other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy&#xD;
        Radiotherapy: No concurrent anticancer radiotherapy Surgery: See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Elias, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Sart-Tilman</name>
      <address>
        <city>Liege</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Pare</name>
      <address>
        <city>Boulogne Billancourt</city>
        <zip>F-92104</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Regional de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLCC Nantes - Atlantique</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital L'Archet - 2</name>
      <address>
        <city>Nice</city>
        <zip>F-06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H.R. de Nimes - Hopital Caremeau</name>
      <address>
        <city>Nimes</city>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR D'Orleans - Hopital de la Source</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>March 23, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2004</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>adenocarcinoma of the colon</keyword>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>liver metastases</keyword>
  <keyword>primary peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

